Abstract
Introduction
Prior exacerbation history and current management opportunities are associated with future exacerbation risk. UK and US studies undertaken as part of the CONQUEST program have identified opportunities to optimise COPD management. It is unknown the extent of similar opportunities in other healthcare systems, such as Australia.
Aims and objectives
To review management opportunities for high-risk COPD patients in Australia, with reference to national and international guidelines, and CONQUEST quality standards1 (identification, assessment, treatment and follow-up for high-risk COPD).
Methods
We utilised the Optimum Patient Care Research Database Australia (OPCRDA), a primary care database of electronic health record (EHR) data containing 900,000 ever-active patients, to identify patients with a COPD diagnosis at high-risk of future exacerbations (≥2 exacerbations in the previous 12 months, based on clinical data and prescribed antibiotics or oral corticosteroids). EHR coded and
free text data were analysed to examine COPD maintenance therapy, smoking cessation support and formal COPD reviews (defined as a recorded COPD review/advice/education or lung function assessment). Cross-sectional analyses were conducted on annual patient cohorts between 2015-2019 to exclude confounding by COVID-19.
Results
The proportion of diagnosed COPD patients defined as high-risk ranged from 30.3% (1620/5340) in 2016 to 24.9% (1476/5992) in 2019 (Table 1). Across the 5-year period, approximately 40% of highrisk patients were not prescribed any COPD maintenance therapy, while the most common therapies were LABA/ICS (~18%) and LAMA/LABA/ICS (~25%). In this population, the proportion of smokers with recorded smoking cessation support reduced from 36% in 2015 to 30% in 2019. Less than 20% of highrisk patients received a COPD review in each study year (Table 1).
Conclusions
There is substantial opportunity to improve the assessment and treatment of patients with diagnosed COPD by reviewing and managing high-risk patients systematically in line with guidelines and CONQUEST quality standards
Prior exacerbation history and current management opportunities are associated with future exacerbation risk. UK and US studies undertaken as part of the CONQUEST program have identified opportunities to optimise COPD management. It is unknown the extent of similar opportunities in other healthcare systems, such as Australia.
Aims and objectives
To review management opportunities for high-risk COPD patients in Australia, with reference to national and international guidelines, and CONQUEST quality standards1 (identification, assessment, treatment and follow-up for high-risk COPD).
Methods
We utilised the Optimum Patient Care Research Database Australia (OPCRDA), a primary care database of electronic health record (EHR) data containing 900,000 ever-active patients, to identify patients with a COPD diagnosis at high-risk of future exacerbations (≥2 exacerbations in the previous 12 months, based on clinical data and prescribed antibiotics or oral corticosteroids). EHR coded and
free text data were analysed to examine COPD maintenance therapy, smoking cessation support and formal COPD reviews (defined as a recorded COPD review/advice/education or lung function assessment). Cross-sectional analyses were conducted on annual patient cohorts between 2015-2019 to exclude confounding by COVID-19.
Results
The proportion of diagnosed COPD patients defined as high-risk ranged from 30.3% (1620/5340) in 2016 to 24.9% (1476/5992) in 2019 (Table 1). Across the 5-year period, approximately 40% of highrisk patients were not prescribed any COPD maintenance therapy, while the most common therapies were LABA/ICS (~18%) and LAMA/LABA/ICS (~25%). In this population, the proportion of smokers with recorded smoking cessation support reduced from 36% in 2015 to 30% in 2019. Less than 20% of highrisk patients received a COPD review in each study year (Table 1).
Conclusions
There is substantial opportunity to improve the assessment and treatment of patients with diagnosed COPD by reviewing and managing high-risk patients systematically in line with guidelines and CONQUEST quality standards
| Original language | English |
|---|---|
| Pages | 10 |
| Number of pages | 1 |
| Publication status | Published - 1 Sept 2023 |
| Event | 8th REG Summit - Lisbon Marriott , Lisbon, Portugal Duration: 16 Mar 2023 → 18 Mar 2023 http://www.regsummit2023.org/ |
Conference
| Conference | 8th REG Summit |
|---|---|
| Country/Territory | Portugal |
| City | Lisbon |
| Period | 16/03/23 → 18/03/23 |
| Internet address |